To dissect the p53-dependent apoptotic pathway, events following induction of temperature sensitive (ts) p53val138 were studied in a Ewing tumor cell line. Transcriptional deregulation of p53 targets ®rst observable after 1 h at 328C preceded activation of caspases and the break-down of mitochondrial respiratory activity. Activation of caspases was ®rst observed 4 h after p53 induction. Using peptide inhibitors we identi®ed activation of caspase 8 upstream of caspases-9 and -3. Although the caspase 8 speci®c inhibitor z-IETD.fmk did not aect translocation of BAX to the mitochondrial membrane and cytochrome C release it almost completely blocked cleavage of the prototype caspase substrate PARP and DNA fragmentation while enforcing mitochondrial depolarization and production of reactive oxygene species (ROS). Activation of caspase 8 did not involve death-domain receptor signaling. Expression of BCL2 only partially suppressed caspase activation but blocked apoptosis. Replacement of the Nterminus of p53val138 by the related VP16 transactivation domain created a ts p53 with a tanscriptional activity indistinguishable from p53val138 until the time of caspase activation. However, the VP16 ± p53 fusion failed to trigger caspases and subsequent induction of the ROS producing gene pig3 paralleled by complete loss of apoptotic activity. These results indicate that p53-dependent transcriptional deregulation, triggering of the caspase cascade and the mitochondrial break-down occur in a timely ordered sequence coordinated by the genuine p53 amino terminus and suggest caspase 8 and PIG3 as key regulatory elements in this process. Oncogene (2000) 19, 4096 ± 4107.
Introduction
Programmed cell death (PCD) alias apoptosis, occurs during normal development to maintain tissue homeostasis and in response to certain types of cellular stress to protect from the fatal consequences of genotoxicity. Several mechanisms of apoptosis have been identi®ed involving mainly three steps: the activation of apoptotic signals by nuclear (i.e. p53) or cell surface sensors (i.e. TNF family receptors), the integration of pro-and anti-apoptotic signals, and the ®nal execution of apoptosis. Propagation of the apoptotic signal occurs through hierarchial proteolytic cleavage of a class of cysteine proteases with aspartic acid speci®city, the caspases. Caspases 3, 6, and 7 have been reported to act as apoptotic executioners at the end of the proteolytic activation cascade (Salvesen and Dixit, 1999) . Caspases 8, 9, and 10 are considered as activator caspases. The latter are characterized by large N-terminal prodomains containing death eector domains or caspase recruitment domains required for interaction with upstream signaling molecules (Thornberry and Lazebnik, 1998) . DNA damage induced PCD has previously been demonstrated to involve break-down of the mitochondrial membrane potential and release of cytochrome C which together with apoptotic protease activating factor 1 (APAF-1) forms an active complex with procaspase 9 and eventually induces caspase 3 for irreversible apoptotic execution (Li et al., 1997) . At this level, the BCL2 family of proteins plays a regulatory role by either supporting cytochrome C release (BAX) or preventing mitochondrial depolarization (BCL2, BCL-xL) or interfering with caspase 9 activation by binding to APAF-1 (BCLxL and BOO) (Shimizu et al., 1999; Antonsson et al., 1997; Kluck et al., 1997; Song et al., 1999; Hu et al., 1998) . Among the earliest events in cellular stress response, nuclear accumulation of the tumor suppressor protein p53 can be observed. P53 integrates not only DNA damage signals but also growth factor signals via a variety of protein phosphorylations. Forced expression of p53 or disruption of its negative regulator MDM2 resulting in nuclear accumulation has been demonstrated to be sucient to elicit an apoptotic response in many cell types even in the absence of DNA damage. Loss of p53 function is frequently associated with resistance to DNA damaging agents and susceptibility to neoplastic transformation. Much of p53's apoptotic activity has been attributed to transcriptional activation of direct downstream targets, including genes that function in known apoptotic pathways (bax, cd95 FAS , killer/dr5), regulate survival factor signaling (IGF-BP3, rgs14), induce apoptosis when overexpressed (pag608/wig-1) or are involved in biochemical events leading to apoptosis (pig genes) (Buckbinder et al., 1995 (Buckbinder et al., , 1997 Israeli et al., 1997; Miyashita and Reed, 1995; Owen-Schaub et al., 1995; Polyak et al., 1997; Varmeh-Ziaie et al., 1997; Wu et al., 1997) . However, in some cell types, apoptosis can be induced by transactivation-de®cient p53 or in the presence of inhibitors of de-novo gene expression, indicating that activation of direct transcriptional down-stream targets of p53 is not generally required for PCD (Sabbatini et al., 1995; Haupt et al., 1995b; Caelles et al., 1994; Wagner et al., 1994) . Instead, redistribution of several apoptotic proteins from cellular depots to the site of action appears to play a pivotal role in PCD. Even in the absence of de novo protein synthesis p53 has been reported to trigger translocation of CD95
FAS from the Golgi apparatus to the outer cellular membrane (Bennett et al., 1998) . Movement of BAX from the cytoplasm to the mitochondrial membrane takes place preceding loss of mitochondrial respiratory activity Wolter et al., 1997; Gross et al., 1998) . BAX is considered to form a channel promoting release of cytochrome C to the cytoplasm where it activates the APAF-1/procaspase 9 complex. The role played by p53 in these processes remains elusive. Apoptosis mediated by members of the TNF receptor family does not require p53. However, cross-talk between p53-dependent and -independent mechanisms of PCD is evident from direct cell-type speci®c up-regulation by p53 of the death receptors CD95
FAS and KILLER/DR5 as well as FAS-ligand. Also, UV but not UV-mimetics cisplatin and melphalan, potent inducers of p53, has been shown to elicit apoptosis via ligand-independent membrane clustering of the TNF-receptor 1 in p53-null breast cancer cells and of CD95 FAS in a human keratinocyte cell line (Sheikh et al., 1998a; Aragane et al., 1998) . In contrast, interaction between CD95 FAS -ligand and its receptor was shown to be required for the response of brain tumor cells to gamma irradiation and several chemotherapeutic agents. However, in these cells, expression of CD95 FAS -ligand was p53-independent while up-regulation of CD95
FAS was seen only in the presence of wild type p53 (Fulda et al., 1998; Muller et al., 1998) . Thymocytes from CD95 FAS de®cient mice, however, have been shown to respond normally to g-irradiation in a p53 dependent manner, indicating that p53-induced apoptosis is not dependent on CD95
FAS expression (Fuchs et al., 1997) . Taken together available data suggest that PCD in response to cytotoxic treatment is a complex process. Consequently, chemo-and radioresistance, the major challenges in cancer therapy, can be caused by several mechanisms. The Ewing family of tumors (EFT), a group of bone and soft-tissue neoplasms in children and young adults, usually respond very well to cytotoxic treatment. However, a high proportion of patients relapse with recurrent, treatment-resistant, disease. P53 is mostly wild type in EFT but tumors giving rise to cell lines frequently carry p53 mutations (Kovar et al., 1993) . In order to de®ne the molecular determinants of apoptosis activated by p53 in the absence of the pleiotropic eects of DNA-damaging treatment we studied SK-N-MC Ewing tumor cells after induction of a stably expressed conditional mutant p53. We show that activation of caspase 8 is an early step in p53-induced apoptosis and that PCD can be blocked by caspase 8 inhibitors without inhibiting the mitochondrial permeability transition and cytochrome C release. We also present evidence for a role of BCL2 downstream of caspase 8 and report that the transcriptional activity of p53 is not sucient to initiate the caspase cascade in these cells.
Results

Dependence of p53 induced apoptosis on the genuine p53 amino terminus
The Ewing tumor cell line SK-N-MC lacks detectable p53 protein due to a truncating deletion mutation (Kovar et al., 1993) . In order to test how these cells respond to restoration and enforced expression of the tumor suppressor the cell cycle distribution of p53 positive and negative cells ± as evidenced by propidium iodide staining ± was¯ow cytometrically assessed after transient transfection of a CMV promoter-driven wild type p53 expression construct. More than 70% of p53 positive cells accumulated at a sub-G1 DNA content indicative of apoptotic chromatin breakdown as compared to less than 10% of cells transfected with the control vector. No signi®cant dierence in the size , and gadd45 and repression of c-myc were ®rst observed 1 h after temperature down-shift while pig3 expression was initiated at 4 h (b) SK-N-MC subclones expressing p53 val138 (SK-VAL3, SK-VAL10, SK-VAL12) or the VP16-p53val138 fusion (SK-VAL8). Individual subclones vary in p53 regulated RNA abundancies. At 6 h after temperature down-shift, SK-VAL3 and SK-VAL8 show comparable changes in target gene induction/repression. Expression of pig3 is delayed and restricted to p53val138 expressing cells of the sub-G1 population was seen at dierent wild type p53 expression levels suggesting that the apoptotic response of SK-N-MC cells was largely independent of the p53 dose (data not shown).
In order to study p53-mediated apoptosis of Ewing tumor cells in more detail temperature sensitive p53val138, the human equivalent of murine p53val135, was stably introduced into SK-N-MC cells and several subclones, SK-VAL3, SK-VAL10 and SK-VAL12, were used for further experimentation. In addition we generated a temperature sensitive subclone SK-VAL8 that stably expresses a modi®ed p53val138 in which amino acids 1 ± 79 were replaced by the herpes simplex virus virion protein 16 (VP16) transactivation domain (amino acids 410 ± 489). Both transactivation domains have previously been demonstrated to activate transcription via association with hTAFII31 and hTAFII70 co-activators of transcription (Thut et al., 1995) . Upon temperature down-shift to 328C for up to 6 h p53val138 and the VP16-p53val138 fusion induced transcription of the p53 targets waf1, mdm2 and bax, and repressed c-myc expression equally well while variability was observed at later times (i.e.13 h) ( Figure  1 ). In contrast, activation of the pig3 gene was delayed and restricted to p53val138 expressing cells. Likewise, only subclones expressing p53 with its genuine Nterminus underwent apoptosis, as demonstrated by activation of the caspase cascade (not shown) and TUNEL staining (Figure 2a ± c) . In p53val138 transfected subclones the size of the apoptotic fraction paralleled inducibility of p53 target genes at 6 h independently of whether there was a further increase (SK-VAL3) or decrease (SK-VAL10, SK-VAL12) of transactivation at 13 h after temperature down-shift (data not shown). While DNA break-down was ®rst detectable after 18 h at 328C in p53val138 expressing cells (Figure 2a ), no DNA fragmentation was observed in VP16 ± p53val138 transfected SK-N-MC even after prolonged times at the permissive temperature (compare b and c in Figure 2 ). This result suggests a function of the genuine p53 amino terminus in p53-induced apoptosis that is independent from its early transcriptional activity.
Distinct phases of apoptotic execution
The ®rst detectable reaction of cells expressing the wild type conformation of p53val138 was transcriptional activation of p53 down-stream targets which was detectable already 1 h after shift to the permissive temperature ( Figure 1a) . Cleavage of caspase substrates such as PARP usually marks the terminal execution phase of apoptosis. In stably p53val138 transfected cells characteristic PARP breakdown products were ®rst observed about 4 h after temperature down-shift (Figure 3a ), when ®rst evidence for activation of the pig3 gene could be obtained (Figure 1 ). In order to con®rm caspase involvement in the execution phase of p53-induced apoptosis, cells were incubated at 328C with the general caspase inhibitory peptide z-VAD.fmk for 18 h after a 2 h-pretreatment at 378C. As shown in Figure 2d , 0.2 mM of the peptide completely inhibited apoptotic DNA fragmentation as evidenced by TU-NEL staining. Caspase 3 is considered to be the major PARP cleaving enzyme and has been previously demonstrated to be implicated in p53val138 mediated apoptosis of Jurkat T-cells (Gao and Tsuchida, 1999) . Similarly, in SK-VAL3 cells incubation with the caspase-3 speci®c inhibitor Ac-DEVD-CHO at high concentration (0.1 mM) largely blocked PARP cleavage ( Figure 4 ) and DNA break-down (Figure 2e ).
At least two presumably independent ways of hierarchial caspase activation cascades exist that converge on activation of caspase 3: One involves release of cytochrome C from mitochondria which forms a complex with APAF-1 and procaspase 9 resulting in autocatalytic activation of caspase 9 and subsequently caspase 3. Cytochrome C release from the mitochondrial intermembrane space is thought to be the consequence of BAX insertion into the membrane and pore formation, respectively membrane depolarization, swelling and rupture. The other caspase activation pathway is initiated by ligand binding to members of the TNF receptor superfamily and involves activation of caspase 8 upstream of caspase 3. Here, the mitochondrial pathway may play an accessory amplifying role in apoptotic execution. In p53val138 expressing SK-N-MC cells at the permissive temperature the mitochondrial membrane potential remained unchanged ( Figure 7 ) and only low amounts of cytochrome C were present in the cytoplasm at the time when PARP cleavage ®rst occurred (Figures 3b, 4 and 5) . Mitochondrial depolarization got evident more than 10 h later ( Figure 7 ) when signi®cant amounts of cytochrome C were released into the cytoplasm ( Figure  5 ). However caspase 9 activation products were detectable already 4 h after temperature down-shift ( Figure 4 ). In contrast to p53-induced apoptosis, PCD elicited by topoisomerase inhibitors etoposide ( Figure  7 ) and actinomycin D (data not shown) in p53 negative SK-N-MC cells followed much faster kinetics. Here, mitochondrial permeability transition and ROS production were already observed after 4 h. Since at high concentration these topoisomerase inhibitors are potent transcriptional blockers this result may indicate that terminal apoptotic execution stimulated by these agents is transcription-independent while the mitochondrial permeability transition in response to p53 may depend on prior activation or repression of certain p53 target genes (i.e. pig3).
Involvement of caspase 8 in p53-induced apotosis
In p53val138 transfected cells proteolytic activation intermediates of caspase 8 appeared concomitantly with PARP cleavage products 4 h after temperature down-shift (Figure 3b) . In order to ®nd out if caspase 8 was activated down-stream or up-stream of caspases 9 and 3 we tested for the presence of the various caspase activation products in cells incubated with inhibitors speci®c for caspase 3 (Ac-DEVD-CHO) (Figure 4 ) or caspase 8 (z-IETD.fmk) ( Figure 5 ). While procaspase 8 activation products remained detectable in Ac-DEVD-CHO treated cells, z-IETD.fmk not only blocked procaspase 8 activation but also PARP cleavage in a dose dependent manner. Activation of caspase 9 was also partially blocked by z-IETD.fmk. No in¯uence on mitochondrial cytochrome C release was observed ( Figure 5 ). Surprisingly, caspase 9 activation and PARP cleavage still remained signi®cantly suppressed by z-IETD.fmk at the time of cytochrome C burst into the cytoplasm and DNA fragmentation was blocked (Figure 2f ). Suppression of apoptosis by inhibition of caspase 8 was con®rmed using an alternative peptide inhibitor, z-LETD.fmkDNA, in the TUNEL assay ( Figure 2g ) and by¯ow cytometric assessment of DNA content in z-IETD.fmk treated and untreated SK-VAL3 cells at 328C (Figure 6 ). The latter approach revealed conversion of the apoptotic response into cell cycle arrest by IETD treatment as indicated by a reduction in S phases. As with the caspase 8 inhibitory peptide, treatment of SK-VAL3 cells with the caspase 9 inhibitor z-LEHD.fmk blocked apoptotic DNA fragmentation (Figure 2g ). These results place caspase 8 upstream of caspases 9 and 3. However, treatment with the caspase 8 inhibitor neither prohibited breakdown of the mitochondrial membrane potential nor interfered with the generation of ROS but rather enforced these processes (Figure 8) . These results suggests a rate limiting function of caspase 8 in p53 induced apoptosis.
BCL2-mediated protection from apoptosis does not block the caspase activation cascade
The mitochondrial permeability transition and consequently the release of cytochrome C has previously been shown to be blocked by overexpression of BCL2 (Yang et al., 1997; Kluck et al., 1997) . Since procaspase 9 and PARP cleavage were blocked by inhibition of caspase 8 independently of mitochondrial depolarization and cytochrome C release in SK-N-MC, we argued that cytochrome C was not responsible for early caspase 9 activation in these cells. Consequently, we suspected activation of the caspase cascade to remain largely unaected by BCL2 overexpression. In order to test this hypothesis, we transiently co-transfected a BCL2 expression plasmid (pCEP4-Bcl2) together with a reporter vector (pEGFP-CMV) that codes for green¯uorescent protein (GFP) into SK-N-MC cells expressing p53val138 at 378C. Twenty-four hours after transfection GFP positive and negative cells were sorted bȳ ow cytometry and incubated at 328C for 6 h. Fractionated protein extracts were prepared and probed for caspases 8 and 9, APAF-1, PARP, BAX, and BCL2 on Western blots (Figure 9a ). In parallel, SK-N-MC cells were transfected with a wild type p53 expression plasmid and GFP in the presence and, for control, in the absence of BCL2 and incubated at 378C for 44 h, ®xed and analysed for DNA content by propidium iodide staining and¯ow cytometry (Figure 9b ). While cleavage of caspases 8 and 9 and of PARP was only slightly reduced in GFP positive as compared to GFP negative cells, apoptosis was clearly Figure 6 Eect of z-IETD.fmk treatment (0.1 mM) on DNA content of SK-VAL3 cells induced to die by temperature downshift for 23 h. DNA contents corresponding to G1 and G2 phases of the cell cycle are indicated on the x-axis Figure 5 Consequences of zIETD.fmk treatment (0 ± 100 mM, as indicated) on the caspase cascade, and on cytochrome C and BAX redistribution. Increasing concentrations of the inhibitor not only blocked processing of procaspase 8 to cleavage intermediates (p43 and p41) and to active caspase 8 (p18) but also PARP cleavage (to degradation products p89 and p24). Procaspase 9 processing was only partially inhibited and no eect was seen on the redistribution of BAX and cytochrome C. Co, Ponceau S stain of the Western blot for loading control inhibited by Bcl2 as evident from a shift of GFP positive cells from a predominantly sub-G1 DNA content in the absence of BCL2 to a G1 DNA content in the presence of BCL2. These results are compatible with our observation that p53 induced early activation of the caspase cascade in SK-N-MC cells is largely independent from mitochondria. Flow cytometric assessment of an apoptotic cell population based on DNA content is made possible by loss of fragmented DNA after permeabilization. Consequently our results also suggest that for apoptotic DNA fragmentation, activation of caspases 8, 9, and 3 is not sucient and may be blocked by inhibition of mitochondrial depolarization.
P53 induced activation of caspase 8 does not involve the death receptor pathway
Among p53 target genes there are cd95 FAS and killer/dr5 encoding members of the TNF receptor superfamily (Owen-Schaub et al., 1995; Takimoto and El-Deiry, 2000) . In addition, p53 has been reported to stimulate CD95 FAS translocation to the cell surface (Bennett et al., 1998) . Upon binding to their respective ligands, FAS-L and TRAIL, these cell surface receptors trigger apoptosis by sequestration of procaspase 8 to the death-inducing signaling complex (DISC) (Juo et al., 1998; Bodmer et al., 2000) We therefore sought to investigate a possible involvement of the death-domain receptors in p53- FAS after paraformaldehyde ®xation, and without ®xation for CD95
FAS exposed on the cell surface only, before and 2 ± 20 h after temperature down-shift, when the caspase cascade was fully active. No changes in total and cell surface CD95
FAS expression levels where detectable (Figure 10a ). In addition, cells were incubated with a CD95 FAS -antagonistic antibody ZB4 at 1 mg/ml 0.5 h before and during a temperature shift period of 18 h. No eect on the caspase activation cascade and on DNA fragmentation was seen (data not shown). In contrast, killer/dr5 expression was observed early after temperature down-shift in SK-VAL3 cells (Figure 10b ). However, killer/dr5 was also found to be induced by the VP16-p53 fusion protein without triggering caspase 8 activation and apoptosis in SK-VAL8 cells. In order to generally exclude involvement of the death receptor pathway in p53 induced PCD we tested the in¯uence of ectopically expressed c-FLIP (cellular FLICE inhibitory protein) which interferes with receptor-mediated caspase activation at the level of DISC formation (Scadi et al., 1999) . As demonstrated in Figure 10c , cotransfection of a c-FLIP expression vector with wild type p53 did not aect cell death of SK-N-MC cells. These results exclude involvement of CD95 FAS and KILLER/DR5 receptors in p53 induced caspase 8 activation and apoptosis of SK-N-MC cells.
Discussion
Using temperature sensitive p53 we followed the sequence of events elicited by p53 accumulation in SK-N-MC Ewing tumor cells in the absence of genotoxic treatment. Essentially three clusters of consecutive steps leading to apoptosis could be distinguished: The transcriptional phase, characterized by strong induction of waf1, mdm2, gadd45, weak activation of bax and repression of c-myc was ®rst detectable at 1 h and peaked 4 ± 6 h after induction of the wild type conformation of p53 by temperature down-shift. Activation of the caspase cascade as indicated by z-VAD.fmk inhibitable cleavage of the prototype caspase substrate PARP was ®rst evident 4 h after p53 induction. At this time, only low amounts of cytochrome C were shed into the cytoplasm, neither an increase in BAX protein levels nor redistribution of BAX to the mitochondrial membrane was observed and the mitochondrial respiratory activity appeared to be still intact. Triggering of the caspase cascade was paralleled by transcriptional activation of the pig3 gene. Eighteen to 20 h after temperature down-shift, BAX insertion into the mitochondrial membrane, loss of mitochondrial membrane potential, generation of ROS and DNA fragmentation were observed. From this sequence of events the question arose if the transcriptional step was solely responsible for the activation of consecutive phases of apoptosis. This problem has previously been addressed by other investigators using either transcriptional inhibitors (i.e. actinomycin D) or p53 with amino terminal mutations that impair its transactivation capability but possibly also other ill-de®ned functions of this domain (Sabbatini et al., 1995; Haupt et al., 1995b; Caelles et al., 1994 with even faster kinetics. The Q22/S23 double mutant, previously shown to be de®cient for transactivation and transrepression (Haupt et al., 1995b) , greatly reduced the apoptotic activity of p53 in SK-N-MC cells but did not completely abolish it (data not shown). This has also been reported for murine GHFT1 cells, in which, however, p53-dependent apoptosis occurred even in the presence of actinomycin D suggestive of a transcription-independent apoptotic function of the amino terminus of p53 (Theis et al., 1997) . We studied the apoptotic propensity of a modi®ed p53, in which the genuine amino terminal transactivation domain has been replaced by the structurally and functionally related domain of HSV VP16 protein. A VP16-p53 chimera has already been used to demonstrate that sequencespeci®c transactivation by p53 is required for its tumor suppressive properties (Pietenpol et al., 1994) . In baby rat kidney cells and mouse embryo ®broblasts the VP16-p53 fusion has also been reported to eciently induce apoptosis (Sabbatini et al., 1997; Attardi et al., 1996) , whereas in GHFT1 cells apoptosis was impaired to the same extent as by the Q22/S23 p53 double mutant. We introduced the val138 mutation into the DNA binding domain of a b Figure 9 Consequences of ectopic BCL2 expression on SK-N-MC cells after p53 induction. (a) Analysis of the caspase cascade: SK-VAL3 cells were transiently co-transfected with a BCL2-and a GFP-expression vector. Twenty four hours later, GFP positive and negative cells were separated¯ow cytometrically, subsequently incubated at 328C for 6 h and subjected to selective plasma membrane permeabilization. Co, Ponceau S stain of the Western blot for loading control. (b) SK-N-MC cells were transfected with a wild type p53 expression vector in the presence of either pCMVneo (Co), or GFP expression plasmid plus pCMVneo (GFP) or BCL2-plus GFP expression vectors (GFP+BCL2) and were ®xed, stained with propidium iodide and analysed by two-color¯ow cytometry for DNA content (PI) 44 h after transfection. Dot plots for cell cycle distribution of GFP negative and positive cells are shown in grey and black, respectively the VP16-p53 chimera thus rendering the transcriptional function temperature-sensitive. Upon temperature down-shift the VP16-p53val138 chimera not only activated transcription of known early responding p53 target genes but also repressed c-myc expression. However, neither induction of the pig3 gene ( Figure  1 ), nor activation of the caspase cascade (data not shown), nor DNA fragmentation was observed, even after prolonged incubation at 328C (Figure 2) . Lack of apoptosis induction may be explainable if fusion to the VP16 domain aected the sequence-speci®c DNA binding properties of p53. A reduced recognition of low-anity binding sites for p53, such as the bax promoter, is considered to be responsible for the inability of temperature-sensitive p53ala143 to induce apoptosis (Friedlander et al., 1996) . However, at the time of caspase activation in p53val138 expressing cells, the level of bax induction in VP16-p53val138 transfected SK-N-MC was comparable to that in p53val138 expressing cells. Bax induction and c-myc repression may be taken as signs for full transcriptional competence of the conditional VP16-p53 fusion at 328C. However, failure of the VP16-p53 fusion to induce pig3 clearly indicates a set of p53 down-stream targets whose activation depends on the genuine p53 amino-terminus. A proline-rich domain between p53 amino acid residues 64 and 92 may represent the critical region in this respect since its deletion resulted in loss of ROS production and pig3 gene transactivation (Venot et al., 1998; Zhu et al., 1999) . Since in p53val138 expressing cells pig3 gene expression was still very weak at onset of the caspase activation cascade, we conclude that for induction of subsequent apoptotic execution steps by p53 in our test system the early transcriptional activity is not sucient supporting previous observations in GHFT1 cells (Theis et al., 1997) . Involvement of caspase 3 in the second phase of PCD could only be demonstrated using high concentrations of Ac-DEVD-CHO. This may be due to overexpression of PARP in EFT, as has been reported previously (Prasad et al., 1990) . Complete inhibition of PARP cleavage was observed using z-IETD.fmk. This result suggests that PARPcleavage in p53 induced apoptosis of SK-N-MC cells is dependent on caspase 8 activity. Since at the same time activation of caspase 9 was only partially suppressed by this compound it is possible that most of the PARP cleaving activity results from a mechanism circumventing caspase 9. Apoptosis may in fact occur independently of caspase 9 since PCD has previously been demonstrated in thymocytes of caspase 9 knock-out mice in response to either CD95 FAS ligand or UV (Hakem et al., 1998) . There is also evidence for rapid and direct caspase 3 activation by caspase 8 in cells in which CD95 FAS -mediated apoptosis is resistant to BCL2 (Scadi et al., 1999). However, the caspase 9 inhibitory peptide z-LEHD.fmk inhibited DNA fragmentation in SK-VAL3 cells to a similar extent as caspases 8 and 3 inhibitors (Figure 2g ). This result indicates that caspase 9 is not dispensable for p53 induced apoptosis compatible with previous observations in knock-out mice (Soengas et al., 1999) . Thus, caspase 9 cleavage of procaspase 3 may be necessary but not sucient to activate caspase 3. Caspase 8 may be required for stimulation of the catalytic activity of caspase 3 as has been suggested previously (Fernandes-Alnemri et al., 1996) . Preliminary results from our group indicate that in the presence of caspase 8 inhibitory peptides z-IETD.fmk and z-LETD.fmk, when caspase 9 activation is only partially reduced, maturation of caspase 3 is blocked at the level of cleavage of the prodomain suggesting that caspases 8 and 9 cooperate in the activation of caspase 3 (data not shown). On the other hand, caspase 8 may also be processed by caspase 3, which participates in a feed-back ampli®cation loop within the caspase cascade (Slee et al., 1999) . In fact caspases 9 and 3 get activated early in p53-induced apoptosis of SK-N-MC cells. It is not clear if the low amounts of cytochrome C released into the cytoplasm long before mitochondrial break-down are sucient to induce this response, which appears to be largely insensitive to BCL2. BCL2 is known to prohibit the burst of cytochrome C into the cytoplasma which, in our system, takes place much later than caspases 8 and 9 activation. Since p53 induced apoptosis was inhibited by BCL2 expression, mitochondrial depolarization and concomitant cytochrome C release may be required for late steps in PCD such as DNA fragmentation. Alternatively, BCL2 may protect from apoptosis without aecting early caspase activation by suppression of p53 target gene transactivation (Zhan et al., 1999) .
Our results clearly demonstrate a rate-limiting function for caspase 8 in the apoptotic process. Previously, triggering of caspase 8 has been reported not only by ligands of the TNF-receptor family including CD95 FAS ligand and TRAIL, but also by several chemotherapeutic drugs (Muller et al., 1998) , ionizing radiation (Fulda et al., 1998) and UV (Aragane et al., 1998) , agents which also trigger p53. CD95 FAS induction was found to be p53-dependent (Owen-Schaub et al., 1995; Muller et al., 1998) while up-regulation of the TRAIL receptor gene killer/dr5 may occur in a p53-dependent as well as in a p53-independent manner (Takimoto and El Deiry, 2000; Aragane et al., 1998; Sheikh et al., 1998b; Wu et al., 1997) . In our study on p53 triggered non-genotoxic apoptosis killer/dr5 expression was clearly induced while no evidence for increased expression or translocation of CD95
FAS from the Golgi to the cell membrane was obtained. In addition, induction of killer/dr5 was unlinked to apoptosis since it did also occur in SK-VAL8 cells upon shift to the permissive temperature. The absence of any modulatory eect on PCD of agents blocking death receptor-mediated apoptosis at either the level of receptor-ligand interaction (CD95 FAS blocking antibody) or at the level of DISC formation (c-FLIP) exclude a role for receptor/ligand interactions in p53 induced activation of caspase 8 in the SK-N-MC cell line. However, p53-mediated upregulation of death receptors may sensitize to external apoptotic stimuli in cell types responding to p53 induction with cell cycle arrest. In addition to the direct eect on caspase 3 activation, caspase 8 has previously been reported to amplify the apoptotic signal on the down-stream caspase cascade by triggering mitochondrial cytochrome C release via cleavage of BID, a proapoptotic BCL2 family member (Bossy-Wetzel and Green, 1999) . In contrast in our test system, inhibition of caspase 8 did not aect cytochrome C release ( Figure 5 ). However, enforcement of mitochondrial transmembrane depolarization and ROS production by z-IETD.fmk implies that caspase 8 does impact on mitochondria in p53-induced apoptosis anyhow. The mechanism, by which caspase 8 in¯uences these mitochondrial changes remains speculative: One consequence of caspase activation is cessation of transcription due to DNA fragmentation by the caspase activated DNase CAD and possibly caspase-mediated inactivation of components of the transcriptional and RNA processing machinery. When p53 is induced but caspase activation is blocked, expression of p53 target genes ± among them pig3 and possibly other genes involved in the generation of ROS (Polyak et al., 1997) ± may continue and the gene products may accumulate to higher levels. In fact, preliminary results indicate an increase in pig3 transcripts in the presence of z-IETD.fmk that may contribute to increased ROS production as observed in our study (data not shown). This hypothesis is also compatible with our observation of dierent kinetics of the mitochondrial permeability transition in p53-independent genotoxic apoptosis elicited by etoposide and actinomycin D as compared to p53 induced PCD (Figure 7) . The former was rapid and transcriptionindependent while the latter was delayed and dependent on the presence of the proline-rich transactivation domain 2 of p53.
In summary, our results suggest, that the transcriptional function of p53 is not sucient to elicit apoptosis in SK-N-MC cells and identify triggering of caspase 8 as a key regulatory event in p53-induced apoptosis. Although activation of the caspase cascade and mitochondrial changes can be independently blocked by caspase inhibitors and BCL2, respectively, caspase 8 could be shown to impact both processes. Considering our results in the context of previously published ®ndings, caspase 8 activation may serve as a master apoptotic switch in receptor mediated, genotoxic and p53-induced apoptosis as well.
Materials and methods
Cells and transfection
The cell line SK-N-MC, kindly supplied by J Biedler (Memorial Sloan Kettering Cancer Center, New York, USA), and all derivative subclones were propagated in RPMI+10% fetal calf serum at 378C. Transfections were performed using LipofectAMIN PLUS 2 Reagent (Life Technologies, Paisley, UK) according to the manufacturer's instructions. Stably transfected subclones were obtained after minimal dilution of transfected cells into 96-well plates and selection with 1 mg/ml G-418 (Geneticin, Life Technologies, Paisley, UK). Temperature sensitive cell lines were manipulated on a 378C heating plate and kept under permanent selective pressure.
Plasmids
Cytomegalovirus early gene promoter based expression vectors (pCMVneo) encoding either wild type p53 (pC53-SN3) (Baker et al., 1990) or p53val138 (pCMVnbp53 ) (Hirano et al., 1995) were kindly supplied by B Vogelstein (Johns Hopkins Oncology Center, Baltimore, MD, USA) and N Tsuchida (Tokyo Medical and Dental University, Tokyo, Japan), respectively. A BCL-2 expression vector (pCEP4-Bcl2) was provided by J Pietenpol (Vanderbit Cancer Center, Nashville, TN, USA), who also kindly supplied a pCEP4 (Invitrogen, Groningen, The Netherlands) based p53 expression plasmid in which the p53 5' portion encoding amino acids 1 ± 79 is replaced by a fragment encoding amino acids 410 ± 489 of herpes simplex virus virion protein VP16 (pCEP4-VP16 80 ± 393) (Pietenpol et al., 1994) . Into this plasmid, we introduced a C?T mutation in p53 codon 138 of the p53 portion by site-directed mutagenesis to create plasmid pCEP-VP16/VAL138 encoding for a temperature sensitive VP16-p53 fusion protein. A pcDNA3 based expression vector encoding for c-FLIP was kindly provided by ME Peter (The Ben May Institute for Cancer Research, University of Chicago, Chicago, USA). A vector encoding bacterial bgalactosidase fused to a SV40 nuclear localization signal has previously been described (Kovar et al., 1996) . The transfection reporter vector pEGFP-CMV was generated by insertion of the cytomegalovirus early gene promoter fragment into the polylinker site of pEGFP-1 plasmid (Clonetech, Palo Alto, CA, USA).
Antibodies and caspase inhibitors
Monoclonal antibodies (mAb) to caspase 8 (C15), and to poly(ADP-ribose) polymerase (PARP) (C-2-10) and the rabbit polyclonal antiserum CM1 to p53 were kindly provided by I Schmitz (DKFZ, Heidelberg, Germany), G Poirier (Centre Hospitalier Universitaire de Quebec, Canada), and B Vojtesek (Masaryk Memorial Cancer Institute, Brno), respectively. The polyclonal rabbit serum to APAF-1 was supplied by X Wang (University of Texas South Western Medical Center, Dallas, TX, USA). The caspase 9 speci®c antibody (Ab2) was purchased from Oncogene Research Products (Calbiochem-Novabiochem, Schwalbach, Germany), the cytochrome C speci®c mAb 7H8.2C12 and a phycoerythrin (PE) conjugated mAb to CD95 FAS (DX2) were from Pharmingen (San Diego, CA, USA). MAbs to BCL2 and BAX (clone N20) were obtained from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The CD95 FAS blocking antibody ZB4 was from Immunotech Inc. (Miami, FL, USA). The b-galactosidase antibody (Z3781) was from Promega (Madison, WI, USA), FITC conjugated anti-mouse (F313) and anti-rabbit (F205) reagents were from DAKO (Vienna, Austria), and peroxidase conjugated anti-mouse and anti-rabbit reagents were from Boehringer Mannheim (Roche Diagnostics, Vienna, Austria).
Cell permeable caspase inhibitory peptides Z-Val-Ala-DLAsp-¯uoromethyl ketone (z-VAD.fmk) and Ac-Asp-Glu-ValAsp-aldehyde (Ac-DEVD-CHO) were purchased from Bachem (Bubendorf, Switzerland), Z-Ile-Glu(OMe)-Thr-Asp(OMe)-uoromethyl ketone (z-IETD.fmk), Z-Leu-Glu(OMe)-ThrAsp(OMe)-¯uoromethyl ketone (z-LETD.fmk) and Z-LeuGlu(OMe)-His-Asp(OMe)-¯uoromethyl ketone (z-LEHD.fmk) were obtained from Enzyme Systems Products (Livermore, CA, USA).
Flow cytometric detection of apoptosis
Fluorescence activated cell sorter analyses (FACS) were performed with a FACSCalibur (BD, Sunnyvale, CA, USA).
DNA content in transiently p53 or control transfected cells was determined essentially according to a previously published protocol (Haupt et al., 1995a) . Forty-four hours after transfection, adherent cells were combined with cells that had detached from the plastic and were ®xed with 70% ice-cold ethanol for at least 1 h. After rehydration and washing in PBS, cells were stained with antibody CM1 for detection of p53 or with an antibody to b-galactosidase, respectively, followed by propidium-iodide (50 mg/ml). DNAcontent in FITC-positive and -negative cells was assessed by two-color FACS analysis.
The generation of ROS was directly followed by FACS analysis for increasing green¯uorescence after incubation of trypsinized cells with 5-(and-6)-chloromethyl-2',7'-dichlorodihydro¯uorescein diacetate (CM-H 2 DCFDA) (Molecular Probes Inc., Eugene, OR, USA) at 10 mmolar for 20 min at 378C.
Mitochondrial depolarization was monitored using the cationic carbocyanine dye JC-1 (Molecular Probes Inc., Eugene, Oregon, USA). Cells were trypsinized, washed and incubated with the dye at a concentration of 10 mmolar for 3 min followed by extensive washings in PBS (six times) and immediate two-color FACS analysis. JC-1 exists as reduorescent aggregates (excitation/emission 488 nm/570 nm) in intact cells due to potential-driven mitochondrial accumulation. Upon mitochondrial depolarization it dissociates to greenuorescent monomers (excitation/emission 488 nm/530 nm). DNA fragmentation was detected by terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick-end labeling (TUNEL) assay using a commercially available kit, the Apoptosis Detection System, Fluorescein (Promega, Madison, WI, USA), following the protocol supplied by the manufacturer. TUNEL-positive cells were recognized by their green¯uorescence in FACS analysis.
Sorting of transfected cells expressing green¯uorescent protein as a transfection marker was accomplished using FACSVentage (BD, Sunnyvale, CA, USA). To minimize temperature¯uctuations during the sorting procedure samples were kept in a 378C waterbath.
Immuno blot analysis
Protein extracts were prepared by selective plasma membrane permeabilization with digitonin to allow for separation of cytoplasmic, mitochondrial, and nuclear+membrane components according to a published protocol (Fiskum et al., 1980) . Brie¯y, cells were washed in isotonic sucrose buer (250 mM sucrose, 10 mM KCl, 1.5 mM MgCl 2 , 1 mM EDTA, 1 mM EGTA, 10 mM HEPES, pH 7.1, plus protease inhibitors 1 mg/ml leupeptin, 2 mg/ml aprotinin, and 0.5 mM PMSF) and subsequently incubated for 1 min at room temperature in 100 ml of the same buer to which 0.05% digitonin has been added, followed by 10 min of centrifugation at 48C. The supernatant contains primarily cytoplasmic proteins. The digitonin-insoluble fraction was further extracted for 10 min in 100 ml ice-cold Triton X-100 buer (0.5% Triton X-100 in isotonic sucrose buer) on ice to obtain mitochondrial components. The insoluble fraction remaining after centrifugation was comprised predominantly by nuclear and cell membrane proteins, which were extracted by boiling in 100 ml SDS-sample buer. Proteins were resolved on reducing SDSpolyacrylamide gels and blotted on to nitrocellulose membranes (Schleicher & Schuell) for Western analysis according to standard procedures.
